fda banning compounded semaglutide & Tirzepatide 2025: Safe Use Guide FDA restricts non-approved compounded GLP-1

Journal of Hepatology

10.1097/00006676-199103000-00013 30 GersteinH

GLP-1 meds may reduce inflammation, improve metabolism, and help people feel less tired and achy

Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients

Of these trials, four compared DPP-4 inhibitors against placebo (SAVOR-TIMI 53, EXAMINE, TECOS, CARMELINA), eight compared GLP-1RA against placebo (ELIXA, LEADER, SUSTAIN-6, EXSCEL, HARMONY, REWIND, PIONEER 6, AMPLITUTE-O) and eleven compared SGLT-2 inhibitors against placebo (EMPA-REG, CANVAS, DECLARE, CREDENCE, DAPA-HF, DAPA CKD, VERTIS-CV, EMPEROR-R, SCORED, SOLOIST-WHF, EMPEROR-P)

McCoy, A